Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Duployez

Showing results (81-90 of 142) with videos related to

Pageof 15
Sort By:
Blood Advances|October 9, 2021
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AMLJuliette Lambert, Jerome Lambert, Xavier Thomas, et al.
Hemasphere|November 15, 2019
Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study GroupAlice Marceau-Renaut, Nicolas Duployez, Benoît Ducourneau, et al.
Oncotarget|February 22, 2018
SNP-array lesions in core binding factor acute myeloid leukemiaNicolas Duployez, Elise Boudry-Labis, Christophe Roumier, et al.
Blood Cancer Journal|September 23, 2022
Hematopoietic differentiation at single-cell resolution in NPM1-mutated AMLMatthieu Duchmann, Romane Joudinaud, Augustin Boudry, et al.
Cancers|January 8, 2020
Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex KaryotypeLaurène Fenwarth, Nicolas Duployez, Xavier Thomas, et al.
Blood Advances|January 13, 2022
Validation and clinical application of transactivation assays for RUNX1 variant classificationMelanie Decker, Anupriya Agarwal, Andreas Benneche, et al.
Blood Cancer Journal|June 23, 2026
Prognostic impact of intensive chemotherapy in patients with TP53-mutated AMLLaurène Fenwarth, Loïc Vasseur, Nicolas Duployez, et al.
Haematologica|December 10, 2020
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical useAuriane Lesieur, Xavier Thomas, Olivier Nibourel, et al.
Blood Advances|November 21, 2023
Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemiaJerome Tamburini, Sarah Mouche, Clement Larrue, et al.
Blood Advances|May 19, 2023
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA studyLoïc Vasseur, Laurène Fenwarth, Jérôme Lambert, et al.
Pageof 15

Showing results (81-90 of 142) with videos related to

Sort By:
Pageof 15
Blood Advances|October 9, 2021
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AMLJuliette Lambert, Jerome Lambert, Xavier Thomas, et al.
Hemasphere|November 15, 2019
Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study GroupAlice Marceau-Renaut, Nicolas Duployez, Benoît Ducourneau, et al.
Oncotarget|February 22, 2018
SNP-array lesions in core binding factor acute myeloid leukemiaNicolas Duployez, Elise Boudry-Labis, Christophe Roumier, et al.
Blood Cancer Journal|September 23, 2022
Hematopoietic differentiation at single-cell resolution in NPM1-mutated AMLMatthieu Duchmann, Romane Joudinaud, Augustin Boudry, et al.
Cancers|January 8, 2020
Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex KaryotypeLaurène Fenwarth, Nicolas Duployez, Xavier Thomas, et al.
Blood Advances|January 13, 2022
Validation and clinical application of transactivation assays for RUNX1 variant classificationMelanie Decker, Anupriya Agarwal, Andreas Benneche, et al.
Blood Cancer Journal|June 23, 2026
Prognostic impact of intensive chemotherapy in patients with TP53-mutated AMLLaurène Fenwarth, Loïc Vasseur, Nicolas Duployez, et al.
Haematologica|December 10, 2020
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical useAuriane Lesieur, Xavier Thomas, Olivier Nibourel, et al.
Blood Advances|November 21, 2023
Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemiaJerome Tamburini, Sarah Mouche, Clement Larrue, et al.
Blood Advances|May 19, 2023
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA studyLoïc Vasseur, Laurène Fenwarth, Jérôme Lambert, et al.
Pageof 15